Department of Surgery, University of California Davis, Sacramento, CA.
Department of Internal Medicine, University of California Davis, Sacramento, CA.
Transplantation. 2018 Jul;102(7):1179-1187. doi: 10.1097/TP.0000000000002096.
Kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is unclear how the willingness to be listed for and accept such kidneys affects waitlist and transplant outcomes.
In a single-center retrospective analysis, HCV+ transplant candidates (N = 169) listed from March 2004 to February 2015 were evaluated. All RNA+ candidates were offered the option to be listed for HCV+ donors. RNA- candidates were listed only for HCV- donors.
Fifty-seven patients (51% of all RNA+ transplant candidates) willing to accept HCV+ donors were listed for both HCV+ and HCV- donor kidneys. During 6-year follow up, 43 (75%) of 57 patients accepting HCV+ versus 19 (35%) of 55 patients not accepting HCV+ received a deceased donor kidney transplant (P < 0.0001). Multivariable analysis demonstrated that willingness to be listed for and accept HCV+ kidneys was associated with receiving deceased donor kidney transplant (P = 0.0016). Fewer patients accepting HCV+ donors (7 [12%] vs 16 [29%]) were removed from the list due to death or deteriorated medical condition (P = 0.0117). Posttransplant patient and graft survival rates were not significantly different. Overall patient survival since the listing (combined waitlist and posttransplant survival) was similar among the groups.
HCV RNA+ candidates had better access to transplantation and similar overall survival before the era of widespread use of direct-acting anti-HCV agents.
从丙型肝炎病毒(HCV)阳性供体进行肾移植可能使 HCV RNA 阳性(RNA+)的候选者受益,但尚不清楚愿意接受此类供体肾脏的意愿如何影响候补名单和移植结果。
在单中心回顾性分析中,评估了 2004 年 3 月至 2015 年 2 月期间列出的 HCV+移植候选者(N=169)。所有 RNA+候选者都有机会选择 HCV+供体。RNA-候选者仅列出 HCV-供体。
57 名(所有 RNA+移植候选者的 51%)愿意接受 HCV+供体的患者同时列入 HCV+和 HCV-供体肾脏的候补名单。在 6 年的随访中,接受 HCV+供体的 57 名患者中有 43 名(75%)接受了已故供体的肾移植,而不接受 HCV+供体的 55 名患者中有 19 名(35%)接受了肾移植(P<0.0001)。多变量分析表明,愿意列入并接受 HCV+肾脏与接受已故供体肾移植有关(P=0.0016)。接受 HCV+供体的患者(7[12%]比 16[29%])因死亡或病情恶化而从名单中删除的人数较少(P=0.0117)。移植后患者和移植物存活率无显著差异。各组之间的总体患者存活率(候补名单和移植后存活率之和)相似。
在广泛使用直接作用抗 HCV 药物之前,HCV RNA+候选者有更好的移植机会和相似的总体生存率。